Drugs for Inclusion Body Myopathy with Early-Onset Paget Disease with or Without Frontotemporal Dementia 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 39)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Amodiaquine |
Approved, Investigational |
Phase 4 |
|
86-42-0 |
2165 |
Synonyms:
||SN 10,751
2aou
4-((7-Chloro-4-quinolinyl)amino)-2-((diethylamino)methyl)phenol
4-((7-Chloro-4-quinolyl)amino)-alpha-(diethylamino)-o-cresol
4-(7-Chloro-quinolin-4-ylamino)-2-diethylaminomethyl-phenol
4-[(7-Chloro-4-quinolinyl)amino]-2-[(diethylamino)methyl]phenol
4-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)phenol
4-[(7-CHLOROQUINOLIN-4-YL)AMINO]-2-[(DIETHYLAMINO)METHYL]PHENOL
5-22-10-00283 (Beilstein Handbook Reference)
7-Chloro-4-(3-diethylaminomethyl-4-hydroxyanilino)
7-Chloro-4-(3-diethylaminomethyl-4-hydroxyanilino)quinoline
7-Chloro-4-(3-diethylaminomethyl-4-hydroxyphenylamino)quinoline
86-42-0
AC-13295
AC1L1D2F
AKOS000538864
Amodiachin
Amodiachinum
Amodiaquin
Amodiaquina
Amodiaquina [INN-Spanish]
amodiaquine
Amodiaquine
Amodiaquine (USAN/INN)
Amodiaquine [USAN:INN:BAN]
amodiaquine hydrochloride
Amodiaquine hydrochloride
Amodiaquine usp24
Amodiaquine USP24
AMODIAQUINE, FLAVOQUINE
Amodiaquine, ring-closed
Amodiaquinum
Amodiaquinum [INN-Latin]
BAS 00327385
Basoquin
Bio-0471
BPBio1_000306
BRN 0300962
BSPBio_000278
C07626
C20H22ClN3O
CAM-AQ 1
Cam-AQ1
|
CAM-AQ1
CAM-AQI
Camochin
Camoquin
Camoquin HCL
Camoquinal
Camoquine
CCRIS 8486
CHEBI:2674
CHEMBL682
CID2165
CPD-10889
CQA
D02922
DB00613
EINECS 201-669-3
Flavoquin
Flavoquine
HSDB 7457
Hydrochloride, amodiaquine
LS-55353
Miaquin
MLS001304065
MolPort-001-924-563
NSC 13453
NSC13453
o-Cresol, 4-[(7-chloro-4-quinolyl)amino]-.alpha.-(diethylamino)- (6CI,7CI,8CI)
Oprea1_019229
Prestwick0_000309
Prestwick1_000309
Prestwick2_000309
Prestwick3_000309
Quinoline, 7-chloro-4-[[3-[(diethylamino)methyl]-4-hydroxyphenyl]amino]-|
Roussel brand OF amodiaquine hydrochloride
S. N. 10751
SMR000718769
SN 10,751
SN 10751
SPBio_002497
Sunoquine
UNII-220236ED28
WR-002977
|
|
2 |
|
Artesunate |
Approved, Investigational |
Phase 4 |
|
88495-63-0 |
6917864 5464098 |
Synonyms:
(3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-ol, hydrogen succinate
112346-66-4
182824-33-5
252637-87-9
4-Oxo-4-(((3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano(4,3-j)-1,2-benzodioxepin-10-yl hydrogen butanedioate
4-oxo-4-{[(3r,5as,6r,8as,9r,10r,12r,12ar)-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}butanoic acid
4-oxo-4-{[(5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}butanoic acid
83507-69-1
88495-63-0
91487-94-4
AC1L23PW
AC1L2XWW
AC1L4FU0
AC1Q5VRV
AKOS004119951
Ambap88495-63-0
Arinate
Arsumax
Arsumax (TN)
Artesunate
Artesunate (superseded RN)
Artesunate (USAN)
Artesunato
Artesunato [INN-Spanish]
Artesunatum
Artesunatum [INN-Latin]
Artesunic acid
Artsuna
AS
BB_NC-1045
Butanedioate, 1-[(3R,5as,6R,8as,9R,10S,12R,12ar)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-J]-1,2-benzodioxepin-10-yl] ester
Butanedioic acid, mono((3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-yl) ester
butanedioic acid, 1-[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl] ester
Butanedioic acid, 1-[(3R,5as,6R,8as,9R,10S,12R,12ar)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-J]-1,2-benzodioxepin-10-yl] ester
Butanedioic acid, mono(decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-yl) ester
C19H28O8
CHEMBL218601
CHEMBL258608
CID105031
CID11520210
CID11988384
CID156252
|
CID5464098
CID65664
CID6917864
CID9821433
CPD000466336
D02482
Dihydroartemisinine-12-alpha-succinate
Dihydroqinghaosusuccinate
dihydroqinghasu hemsuccinate
Dihydroqinghasu hemsuccinate
Dihydroqinghasu hemsuccinic acid
FT-0082543
HMS2051I14
HMS2090L16
HSDB 7458
I06-0204
LS-177760
LS-187735
Malacef
Malartin
MLS000759445
MLS001424053
MolPort-001-732-325
MolPort-006-392-384
NCI60_039350
NSC712571
Nuartez
Plasmotrim
Plasmotrin
Qinghaozhi
Quinghaosu reduced succinate ester
S2265_Selleck
SAM001246628
SM 804
SMR000466336
Sodium artesunate
STK801911
Succinyl dihydroartemisinin
UNII-60W3249T9M
WR 256283
WR-256283
|
|
3 |
|
Primaquine |
Approved |
Phase 4 |
|
90-34-6 |
4908 |
Synonyms:
(-)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine
()-Primaquine
(-)-Primaquine
(+)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine
(+)-Primaquine
(+/-)-Primaquine
1,4-Pentanediamine, N4-(6-methoxy-8-quinolinyl)- (9CI)
4-22-00-05817 (Beilstein Handbook Reference)
4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine
63-45-6
63-45-6 (1:2 PO4)
6-Methoxy-8-(4-amino-1-methylbutylamino)quinoline
6-Methoxy-8-[(4-amino-1-methylbutyl)amino]quinoline
6-Methoxy-8-[4-amino-1-methylbutylamino]quinoline
8-((4-amino-1-Methylbutyl)amino)-6-methoxyquinoline
8-((4-Amino-1-methylbutyl)amino)-6-methoxyquinoline
8-(4-Amino-1-m
8-(4-amino-1-methylbutylamino)-6-Methoxyquinoline
8-(4-Amino-1-methylbutylamino)-6-methoxyquinoline
8-[(4-Amino-1-methylbutyl)amino]-6-methoxyquinoline
90-34-6
AB00053529
AC1L1J80
AC1Q4F0C
AC1Q4F4Q
Boucher and muir brand OF primaquine phosphate
BPBio1_000674
BRN 0019337
BSPBio_000612
BSPBio_002223
C07627
CCRIS 4109
CHEBI:8405
CHEMBL506
CID4908
D08420
DB01087
Diphosphate, primaquine
DivK1c_000806
dl-Primaquine
EINECS 201-987-2
ethylbutylamino)-6-methoxyquinoline
HMS2090J17
HSDB 6516
I08-0048
IDI1_000806
Kanaprim
Kanaprim (TN)
KBio1_000806
KBio2_001310
KBio2_003878
KBio2_006446
KBio3_001723
KBioGR_000967
KBioSS_001310
LS-141312
MolPort-001-794-628
|
N(4)-(6-methoxyquinolin-8-yl)pentane-1,4-diamine
N-(5-aminopentan-2-yl)-6-methoxyquinolin-8-amine
N~4~-[6-(methyloxy)quinolin-8-yl]pentane-1,4-diamine
N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine
NCGC00178754-01
NCGC00178754-02
NCI60_001035
NCI60_005887
neo-Quipenyl
Neo-Quipenyl
NINDS_000806
NSC 27296
NSC27296
Oprea1_546209
Phosphate, primaquine
PQ
Prestwick0_000476
Prestwick1_000476
Prestwick2_000476
Prestwick3_000476
Primachin
Primachina
Primachina [DCIT]
Primachinum
Primacin
Primaquin
Primaquina
Primaquina [INN-Spanish]
Primaquine
PRIMAQUINE
Primaquine (INN)
Primaquine [INN:BAN]
Primaquine Bis-Phosphoric Acid
Primaquine diphosphate
Primaquine phosphate
Primaquinum
Primaquinum [INN-Latin]
Quinoline, 8-(4-amino-1-methylbutylamino)-6-methoxy
Quinoline, 8-[(4-amino-1-methylbutyl)amino]-6-methoxy- (6CI,8CI)
S. N. 13272
SMP1_000263
SN 13,272
SN 13272
SPBio_000674
SPBio_002551
Spectrum_000830
Spectrum2_000887
Spectrum3_000552
Spectrum4_000484
Spectrum5_001363
STOCK5S-90838
TG1-296
TG1-297
UNII-MVR3634GX1
WLN: T66 BNJ HO1 JMY1&3Z
WR 2975
|
|
4 |
|
Dihydroartemisinin |
Experimental, Investigational |
Phase 4 |
|
71939-50-9 |
6918483 |
Synonyms:
(3R,5aS,6R,8aS,9R,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10-ol
[3R-(3.alpha.,5a.beta.,6.beta.,8a.beta.,9.alpha.,10.alpha.,12.beta.,12aR*)]-Decahydro-10-hydroxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4.3-j]-1,2-benzodioxepin
1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol(Dihydroartemisinin)
71939-50-9
81496-81-3
AC1L32PY
AC1L9UV6
AC-2067
Ambotz71939-50-9
Artenimol
Artenimol (INN)
beta-Dihydroartemisinin
CHEBI:207229
CHEMBL25164
CID107770
|
CID456410
CID6918483
Cotecxin
D07362
D3793
Dihydroartemisinin
Dihydroartemisinine
Dihydroqinghaosu
Dihydroquinghaosu
Dihydroquinghoasu
GNF-PF-5634
JAV-110
LS-64240
VM3352
|
|
5 |
|
Piperaquine |
Experimental, Investigational |
Phase 4 |
|
4085-31-8 |
5079497 |
Synonyms:
1,3-bis(1-(7-chloro-4'-quinolyl)-4'-piperazinyl)propane
1,3-bis(4-(7'-chloro-4'-quinoline)-1-piperazine)
1,3-bis[4-(7-chloroquinolin-4-yl)piperazin-1-yl]propane
4,4'-(propane-1,3-diyldipiperazine-4,1-diyl)bis(7-chloroquinoline)
4085-31-8
5-23-03-00072 (Beilstein Handbook Reference)
7-chloro-4-[4-[3-[4-(7-chloroquinolin-4-yl)piperazin-1-yl]propyl]piperazin-1-yl]quinoline
83764-65-2
AC1L3UA1
AC1Q3T7B
AR-1F7471
BRN 0905079
|
C29H32Cl2N6
CHEMBL303933
CID122262
FT-0082661
I06-1673
LS-142194
piperaquine
Piperaquinoline
Quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro- (9CI)
Quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro-)
ST51053186
|
|
6 |
|
Artemisinins |
|
Phase 4 |
|
|
|
7 |
|
Artemisinine |
|
Phase 4 |
|
|
|
8 |
|
Antiparasitic Agents |
|
Phase 4 |
|
|
|
9 |
|
Antiprotozoal Agents |
|
Phase 4 |
|
|
|
10 |
|
Anti-Infective Agents |
|
Phase 4 |
|
|
|
11 |
|
Antimalarials |
|
Phase 4 |
|
|
|
12 |
|
Anthelmintics |
|
Phase 4 |
|
|
|
13 |
|
Antiviral Agents |
|
Phase 4 |
|
|
|
14 |
|
Lumefantrine |
Approved |
Phase 3 |
|
82186-77-4 |
6437380 |
Synonyms:
(+-)-2,7-dichloro-9-((Z)-P-Chlorobenzylidene)-a-((dibutylamino)methyl)fluorene-4-methanol
(+-)-2,7-dichloro-9-((Z)-P-Chlorobenzylidene)-alpha-((dibutylamino)methyl)fluorene-4-methanol
(+-)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-alpha((dibutylamino)methyl)fluorene-4-methanol
(+-)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-alpha-((dibutylamino)methyl)fluorene-4-methanol
(+-)-2,7-dichloro-9-((Z)-P-Chlorobenzylidene)-α-((dibutylamino)methyl)fluorene-4-methanol
(±)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-α-((dibutylamino)methyl)fluorene-4-methanol
120583-69-9
2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-(4-chlorobenzylidene)-9H-fluoren-4-yl]ethanol
2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-[(4-chlorophenyl)methylidene]fluoren-4-yl]ethanol
2-dibutylamino-1-[2,7-dichloro-9-(4-chloro-Benzylidene)-9H-fluoren-4-yl]-ethanol
2-Dibutylamino-1-[2,7-dichloro-9-(4-chloro-benzylidene)-9H-fluoren-4-yl]-ethanol
2-dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(Z)-ylidene]-9H-fluoren-4-yl}-ethanol
2-Dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(Z)-ylidene]-9H-fluoren-4-yl}-ethanol
82186-77-4
AC1O5NKD
AC-4542
benflumetol
Benflumetol
Benflumetol, (-)-isomer
Benflumetol, (+)-isomer
|
Benflumetol, (+-)-isomer
Bio-0132
C30H32Cl3NO
CHEBI:156095
CHEMBL38827
CID6437380
Coartem
D03821
DB06708
dl-Benflumelol
DL-Benflumelol
HSDB 7210
I14-7746
LS-177674
Lumefantrine
Lumefantrine (INN)
Lumefantrine [INN:BAN]
MolPort-006-394-826
NCGC00167490-01
UNII-F38R0JR742
|
|
15 |
|
Artemether |
Approved |
Phase 3 |
|
71963-77-4 |
68911 9796294 119380 |
Synonyms:
( )-alpha-Artemether
(1R,4S,5R,8S,9R,10S,12R,13R)-10-methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecane
(1R,4S,5R,8S,9R,10S,12R,13R)-10-Methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecane
(3alpha,5abeta,6beta,8abeta,9alpha,10beta,12beta,12aR*)-isomer of artemether
(3r,5as,6r,8as,9r,10r,12r,12ar)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene
(3R,5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepine
(3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-10-methoxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin
(5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene
.beta.-Artemether
.beta.-Dihydroartemisinin methyl ether
.beta.-Methylether of 11-epi-dihydroartemisinin
10-methoxy-1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane
10-Methoxy-1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane
159573-83-8
3,12-Epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin, decahydro-10-methoxy-3,6,9-tri
71939-51-0
71963-77-4
74784-06-8
80286-56-2
93787-85-0
AC1L2APD
AC1L2XO8
AC1L9SH2
AC1L9UV0
AC1MI2ZX
AC1Q6Z74
AC1Q6Z7V
alpha-Artemether
alpha-Dihydroartemisinin methyl ether
AR-1A4424
Arteannuin ether
Artemetero
Artemetero [INN-Spanish]
Artemether
Artemether (INN)
Artemether [INN]
artemether, (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,12aR*))-isomer
artemether[inn]
Artemetheri
Artemetherum
Artemetherum [INN-Latin]
Artemisininelactol methyl ether
Artemos
Artenam
Artesaph
Artesian
Artimist
Artmether
b-Artemether
b-Dihydroartemisinin methyl ether
beta-Artemether
|
beta-Dihydroartemisinin methyl ether
BRN 5948416
C16H26O5
CHEBI:195280
CHEMBL411864
CHEMBL512315
CID10266705
CID104888
CID3062122
CID456408
CID500199
CID6483308
CID6712286
CID68911
CID9796294
CID9796295
CPD000469218
D02483
DB06697
dihydroartemisinin methyl ether
Dihydroartemisinin methyl ether
Dihydroqinghaosu methyl ether
Dihydroquinghaosu methyl ether
Falcidol
Gvither
HMS2052L09
HSDB 7456
I06-0205
KST-1A8041
LS-176935
LS-64237
Malartem
methyl-dihydroartemisinine
Methyl-dihydroartemisinine
MLS001424249
NCI60_022891
NSC 665970
NSC665970
O-Methyldihydroartemisinine
Paluther
rither
S2264_Selleck
SAM001246799
SM 224
SM 229
SM-224
SMR000469218
UNII-C7D6T3H22J
β-artemether
β-dihydroartemisinin methyl ether
|
|
16 |
|
Lactitol |
Approved, Investigational |
Phase 3 |
|
585-88-6, 585-86-4 |
493591 |
Synonyms:
(2S,3R,4R,5R)-4-{[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}hexane-1,2,3,5,6-pentol
4-O-a-D-Glucopyranosyl-D-glucitol
4-O-alpha-delta-Glucopyranosyl-delta-glucitol
4-O-alpha-D-Glucopyranosyl-D-glucitol
4-O-α-D-glucopyranosyl-D-glucitol
a-D-GLC-(1->4)-D-GLC-ol
a-D-GLCP-(1->4)-D-GLC-ol
a-D-Glucosyl-(1->4)-D-glucitol
alpha-D-GLC-(1->4)-D-GLC-ol
alpha-D-GLCP-(1->4)-D-GLC-ol
alpha-D-Glucosyl-(1->4)-D-glucitol
Amalti syrup
Amalty MR 100
|
D-4-O-alpha-D-Glucopyranosylglucitol
delta-4-O-alpha-delta-Glucopyranosylglucitol
delta-Maltitol
D-Maltitol
Lactitol
Lactitolum
Malbit
Malti MR
Maltisorb
Maltit
α-D-GLC-(1->4)-D-GLC-ol
α-D-GLCP-(1->4)-D-GLC-ol
α-D-glucosyl-(1->4)-D-glucitol
|
|
17 |
|
leucovorin |
Approved |
Phase 2, Phase 3 |
|
58-05-9 |
6006 143 |
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R,S)-5-Formyltetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-formyltetrahydrofolate
5-Formyltetrahydrofolate
5-formyltetrahydrofolic acid
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formylTHF
Acid, folinic
Acide folinique
Acido folinico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
Citrovorum factor
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
|
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monosodium salt
Leucovorinum
Leukovorin
Leukovorum
Levoleucovorin
L-leucovorin
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
Rescuvolin
Welcovorin
Wellcovorin
|
|
18 |
|
Sulfadoxine |
Approved, Investigational |
Phase 2, Phase 3 |
|
2447-57-6 |
17134 |
Synonyms:
2447-57-6
46810_RIEDEL
4-Amino-N-(5,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide
4-amino-N-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide
4-amino-N-[5,6-bis(methyloxy)pyrimidin-4-yl]benzenesulfonamide
4-Sulfanilamido-5,6-dimethoxypyrimidine
4-Sulphanilamido-5,6-dimethoxypyrimidine
5-25-13-00306 (Beilstein Handbook Reference)
6-(4-Aminobenzenesulfonamido)-4,5-dimethoxypyrimidine
AB00514044
AC-11921
AC1L29DT
AC1Q46GG
Ambap2447-57-6
BPBio1_001286
BRD-K55250441-001-03-1
BRN 0625453
BSPBio_001168
C07630
CAS-2447-57-6
CHEBI:9329
CHEMBL1539
CID17134
D00580
DB01299
EINECS 219-504-9
Fanasil
Fanzil
HMS1571K10
HMS2090P07
HMS2094C19
I09-0529
LS-31247
MLS002154150
MolPort-003-850-341
N'-(5,6-Dimethoxy-4-pyrimidyl)sulfanilamide
N(sup 1)-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide
N1-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide
NCGC00016612-01
NCGC00016612-02
|
Orthosulfin
Prestwick0_001094
Prestwick1_001094
Prestwick2_001094
Prestwick3_001094
Ro 4-4393
Ro-4-4393
Roche brand OF sulfadoxine
S2511_Selleck
S7821_SIGMA
Sanasil: Sulfadoxine: Sulformetoxin
SMR000857259
Solfadossina
Solfadossina [DCIT]
SPBio_003054
Sulfadoxin
Sulfadoxina
Sulfadoxina [INN-Spanish]
Sulfadoxine
SULFADOXINE
Sulfadoxine (JAN/USP/INN)
Sulfadoxine [USAN:INN:BAN:JAN]
Sulfadoxine roche brand
Sulfadoxinum
Sulfadoxinum [INN-Latin]
Sulformethoxine
Sulformetoxine
Sulforthomidine
Sulphadoxina
Sulphadoxine
Sulphadoxinum
Sulphormethoxine
Sulphormetoxin
Sulphorthodimethoxine
Sulphorthomidine
UNII-88463U4SM5
WR 4073
WR 4873
ZINC00002094
|
|
19 |
|
Pyrimethamine |
Approved, Investigational, Vet_approved |
Phase 2, Phase 3 |
|
58-14-0 |
4993 |
Synonyms:
2,4-diamino-5-(4-Chlorophenyl)-6-ethylpyrimidine
2,4-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine
2,4-diamino-5-(P-Chlorophenyl)-6-ethylpyrimidine
2,4-Diamino-5-(p-chlorophenyl)-6-ethylpyrimidine
2,4-Diamino-5-(P-chlorophenyl)-6-ethylpyrimidine
2,4-diamino-5-Chlorophenyl-6-ethylpyrimidine
2,4-Diamino-5-chlorophenyl-6-ethylpyrimidine
46706_FLUKA
46706_RIEDEL
4753 r.p
4753 R.P.
5-(4-chlorophenyl)-2,4-diamino-6-ethylpyrimidine
5-(4'-Chlorophenyl)-2,4-diamino-6-ethylpyrimidine
5-(4-Chlorophenyl)-6-ethyl-2,4-diaminopyrimidine
5-(4-Chlorophenyl)-6-ethyl-2,4-pyrimidi nediamine
5-(4-Chlorophenyl)-6-ethyl-2,4-pyrimidinediamine
5-(4-CHLOROPHENYL)-6-ETHYL-2,4-PYRIMIDINEDIAMINE
5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine
5-(4-CHLORO-PHENYL)-6-ETHYL-PYRIMIDINE-2,4-DIAMINE
5-(p-chlorophenyl)-6-ethyl-2,4-diaminopyrimidine
5-[4-Chlorophenyl]-6-ethyl-2,4-pyrimidinediamine
58-14-0
AB00052084
AC1L1JDI
AC-7879
AI3-25005
Aventis brand OF pyrimethamine
Aventis Brand of Pyrimethamine
AZT + Pyrimethamine combination
BIDD:GT0149
BIDD:PXR0173
BPBio1_000147
BRD-K88429204-001-05-4
BRN 0219864
BSPBio_000133
BSPBio_003282
BW 5063
BW 50-63
C07391
C12H13ClN4
CAS-58-14-0
CCRIS 546
CD
CHEBI:8673
CHEMBL36
Chloridin
Chloridine
Chloridyn
CID4993
CP6
CPD000058714
CRL-8131 & Pyrimethamine
CRL-8142 & Pyrimethamine
D00488
D011739
Darachlor
Daraclor
Darapram
Daraprim
Daraprim (TN)
Daraprime
Daraprin
DB00205
Diaminopyritamin
Disulone
DivK1c_000652
EINECS 200-364-2
Erbaprelina
Ethylpyrimidine
EXR-101
Fansidar
Fansidar (Pyrimethamine/Sulfadoxine)
glaxo Wellcome brand OF pyrimethamine
Glaxo Wellcome Brand of Pyrimethamine
GlaxoSmithKline brand OF pyrimethamine
GlaxoSmithKline Brand of Pyrimethamine
HMS1568G15
HMS1920N12
HMS2092E13
HMS502A14
IDI1_000652
KBio1_000652
KBio2_001386
|
KBio2_003954
KBio2_006522
KBio3_002502
KBioGR_001007
KBioSS_001386
Khloridin
L000713
Lactoferrin B & Pyrimethamine
Lactoferrin H & Pyrimethamine
LS-238
m alocid
Malacid
Malocid
Malocide
Maloprim
MCB-3837
MLS000028606
MLS001148621
MLS002454446
MLS002701881
MolPort-001-783-655
NCGC00016256-01
NCGC00016256-02
NCGC00023188-03
NCGC00023188-04
NCGC00023188-05
NCGC00023188-06
NCGC00023188-07
nchembio.215-comp13
nchembio.87-comp22
NCI60_002604
NCI-C01683
NCIOpen2_008313
NINDS_000652
NSC 3061
NSC3061
NSC-3061
Oxaquin
Pirimecidan
Pirimetamin
Pirimetamina
Pirimetamina [INN-Spanish]
Pirimetamina [Spanish]
Prestwick_504
Prestwick0_000037
Prestwick1_000037
Prestwick2_000037
Prestwick3_000037
Primethamine
Pyremethamine
Pyrimethamin
pyrimethamine
Pyrimethamine
Pyriméthamine
Pyrimethamine (JAN/USP/INN)
Pyrimethamine (Pyr)
Pyrimethamine [USAN:INN:BAN:JAN]
Pyrimethamine Hcl
Pyrimethaminum
Pyrimethaminum [INN-Latin]
RP 4753
S2006_Selleck
SAM002554921
SMR000058714
SPBio_000672
SPBio_002054
Spectrum_000906
SPECTRUM1500520
Spectrum2_000886
Spectrum3_001701
Spectrum4_000494
Spectrum5_001447
TCMDC-123831
TCMDC-125860
Tindurin
Tindurine
Tinduring
UNII-Z3614QOX8W
Wellcome brand OF pyrimethamine
Wellcome Brand of Pyrimethamine
WLN: T6N CNJ BZ DZ ER DG& F2
WR 2978
ZINC00057464
|
|
20 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 2, Phase 3 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
ácido fólico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
AI3-26387
AKOS000503224
Antianemia factor
Apo-Folic
ARONIS014410
b9, Vitamin
BIDD:ER0563
BIDD:GT0641
BIF0608
bmse000299
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat b activ
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
Facid
Factor U
FOL
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
folic acid
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
|
Folipac
Folsaeure
Folsan
Folsaure
Folsäure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
Incafolic
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
Liver lactobacillus casei factor
Liver Lactobacillus casei factor
LS-2157
Millafol
Mission prenatal
Mittafol
MLS001304016
MLS001335861
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-Pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
nchembio.108-comp10
Nifolin
Nifolin [Denmark]
NINDS_000494
Novofolacid
Novofolacid [Canada]
N-Pteroyl-L-glutamate
N-pteroyl-L-glutamic acid
N-Pteroyl-L-glutamic acid
NSC 3073
PGA
PGA (VAN)
Prestwick_230
Prestwick3_000627
PteGlu
Pteroylglutamate
Pteroylglutamic acid
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
Serum Folate Level
SMP2_000137
SMR000471860
SPBio_001357
Spectrum_001381
SPECTRUM1502020
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin b9
Vitamin B9
Vitamin Bc
Vitamin BC
Vitamin be
Vitamin Be
Vitamin m
Vitamin M
|
|
21 |
|
Artemether, Lumefantrine Drug Combination |
|
Phase 3 |
|
|
|
22 |
|
Folic Acid Antagonists |
|
Phase 2, Phase 3 |
|
|
|
23 |
|
Vitamin B Complex |
|
Phase 2, Phase 3 |
|
|
|
24 |
|
Folate |
|
Phase 2, Phase 3 |
|
|
|
25 |
|
Vitamin B9 |
|
Phase 2, Phase 3 |
|
|
|
26 |
|
Vaccines |
|
Phase 1, Phase 2 |
|
|
|
27 |
|
Immunologic Factors |
|
Phase 1, Phase 2 |
|
|
|
28 |
|
Aluminum hydroxide |
Approved, Investigational |
Phase 1 |
|
21645-51-2 |
|
Synonyms:
Aluminio hidróxido
Aluminium hydroxide
Aluminium hydroxide gel, dried
Aluminium hydroxide, dried
|
Aluminum hydroxide gel, dried
Aluminum hydroxide, dried
Dried aluminium hydroxide
Dried aluminum hydroxide gel
|
|
29 |
|
Neomycin |
Approved, Vet_approved |
Phase 1 |
|
1404-04-2 |
8378 |
Synonyms:
(1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside
(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol
11025-81-3
119-04-0
1393-86-8
1404-04-2
1405-10-3 (sulfate (salt))
4-18-00-07476 (Beilstein Handbook Reference)
72131_FLUKA
AB00443887
AC1L1QVH
Actilin
Actiline
Antibiotic 10676
Antibiotic produced by Streptomyces decaris. Neomycin B
Antibiotique
BDG-(1-4)CYY-(5-1)RIB-(3-1)IDG
BDG-(1-4)NEB-(5-1)RIB-(3-1)NED
Biosol
BPBio1_000326
BRN 0101621
BSPBio_000296
Bykomycin
C01737
C23H46N6O13
C25H50N6O13
Caswell no. 595
Caswell No. 595
CCRIS 5462
CHEBI:7508
CID8378
D05140
DB00452
DB00994
D-Streptamine, O-2,6-diamino-2,6-dideoxy-.beta.-L-idopyranosyl-(1.->3)-O-.beta.-D-ribofuranosyl-(1->5)]-O-[2,6-diamino-2,6-dideoxy-.alpha.-D-glucopyranosyl-(1->4)]-2-deoxy
EINECS 204-292-2
EINECS 215-766-3
Endomixin
Enterfram
EPA Pesticide Chemical Code 006303
Fradiomycin
Fradiomycin b
Fradiomycin B
Fradiomycin sulfate
Fradiomycin Sulfate
Fradiomycinum
Framicetina
Framicetina [INN-Spanish]
Framycetin
Framycetin (INN)
Framycetin [INN:BAN:DCF]
Framycetine
Framycetine [INN-French]
Framycetinum
Framycetinum [INN-Latin]
Framygen
Fraquinol
HMS2089P15
HSDB 3242
Kaomycine
Lidamycin Creme
LS-96091
|
LS-96095
MolPort-003-938-736
Myacine
Myacyne
Mycifradin
Mycifradin-N
Myciguent
N1142_SIGMA
NCGC00179612-01
Neobiotic
Neobrettin
Neofracin
Neo-Fradin
Neolate
Neo-Mantle Creme
Neomas
Neomcin
Neomicina
Neomicina [DCIT]
Neomin
Neomix
neomycin
Neomycin
NEOMYCIN AND POLYMYXIN B SULFATES
Neomycin b
NEOMYCIN B
Neomycin b sulfate
Neomycin B sulfate
Neomycin B Sulfate
Neomycin palmitate
Neomycin solution
Neomycin sulfate
Neomycin Sulfate
NEOMYCIN SULFATE
Neomycin sulphate
Neomycin Sulphate
Neomycin trisulfate salt hydrate
Neomycine
Neomycine [INN-French]
Neomycinum
Neomycinum [INN-Latin]
Neo-Rx
Neosulf
Nivemycin
NMY
Palmitate, neomycin
PIMAVECORT
Prestwick3_000158
Soframycin
Soframycin Ophthalmic
Soframycine
ST075177
Sulfate, fradiomycin
Sulfate, neomycin
Tuttomycin
UNII-4BOC774388
UNII-I16QD7X297
USAF CB-19
Vonamycin
VONAMYCIN
Vonamycin powder V
Vonamycin Powder V
|
|
30 |
|
Antacids |
|
Phase 1 |
|
|
|
31 |
|
Adjuvants, Immunologic |
|
Phase 1 |
|
|
|
32 |
|
Anti-Ulcer Agents |
|
Phase 1 |
|
|
|
33 |
|
Gastrointestinal Agents |
|
Phase 1 |
|
|
|
34 |
|
chloroquine |
Approved, Investigational, Vet_approved |
|
|
54-05-7 |
2719 |
Synonyms:
( -)-Chloroquine
(-)-Chloroquine
(+)-Chloroquine
(R)-(-)-Chloroquine
{4-[(7-chloroquinolin-4-yl)amino]pentyl}diethylamine
3377 RP opalate
3545-67-3
50-63-5
54-05-7
56598-66-4
58175-86-3
58175-87-4
7-Chloro-4-((4-(diethylamino)-1-methylbutyl)amino)quinoline
7-Chloro-4-[[4-(diethylamino)-1-methylbutyl]amino]quinoline
AB00053436
AC1L1EB8
AC1Q2ZA7
AC1Q2ZA8
Amokin
Aralen
Aralen HCl
Arechin
Arechine
Arequin
Arolen
Arthrochin
Artrichin
Avlochlor
Avloclor
Bemaco
Bemaphate
Bemaphic acid
Bemasulph
Benaquin
Bipiquin
BPBio1_000655
BRD-A91699651-065-01-1
BRN 0482809
BSPBio_000595
BSPBio_002001
C07625
C18H26ClN3
Capquin
CCRIS 3439
CHEBI:3638
CHEMBL76
Chemochin
Chingamin
Chloraquine
Chlorochin
Chlorochine
Chlorochinum
Chloroin
Chloroquin
Chloroquina
chloroquine
Chloroquine
Chloroquine (USP/INN)
Chloroquine (VAN)
Chloroquine [USAN:INN:BAN]
Chloroquine Bis-Phosphoric Acid
Chloroquine phosphate
Chloroquine Phosphate
Chloroquine sulfate
Chloroquine sulphate
Chloroquinium
Chloroquinum
Chloroquinum [INN-Latin]
Chlorquin
CID2719
Cidanchin
Clorochina
Clorochina [DCIT]
Cloroquina
Cloroquina [INN-Spanish]
Cocartrit
CQ
CU-01000012392-2
D02366
Dawaquin
DB00608
Delagil
Dichinalex
DivK1c_000404
EINECS 200-191-2
Elestol
Gontochin
Gontochin phosphate
Heliopar
HMS2090O03
HSDB 3029
Hydroxychloroquine Sulfate
IDI1_000404
Imagon
|
Ipsen 225
Iroquine
KBio1_000404
KBio2_000592
KBio2_003160
KBio2_005728
KBio3_001221
KBioGR_000778
KBioSS_000592
Khingamin
Klorokin
Lapaquin
Lopac0_000296
LS-141726
Malaquin
Malaquin (*Diphosphate*)
Malaren
Malarex
Mesylith
Miniquine
MolMap_000009
MolPort-001-783-623
N(4)-(7-chloro-4-Quinolinyl)-N(1),N(1)-diethyl-1,4-pentanediamine
N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine
N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine
N4-(7-chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine
NCGC00015256-04
NCGC00162120-01
nchembio.215-comp4
nchembio.368-comp8
nchembio.87-comp17
NCI60_000894
Neochin
NINDS_000404
Nivachine
Nivaquine
Nivaquine b
Nivaquine B
NSC 187208
NSC14050
NSC187208
Pfizerquine
Plaquenil
Prestwick0_000548
Prestwick1_000548
Prestwick2_000548
Prestwick3_000548
Quinachlor
Quinagamin
Quinagamine
Quinercyl
Quingamine
Quinilon
Quinoscan
Resochen
Resochin
Resoquina
Resoquine
Reumachlor
Reumaquin
Rivoquine
Ro 01-6014/N2
Ronaquine
Roquine
RP 3377
RP-3377
Sanoquin
Silbesan
Siragan
SMP2_000034
SN 6718
SN-7618
Solprina
Sopaquin
SPBio_000174
SPBio_002516
Spectrum_000132
Spectrum2_000127
Spectrum3_000341
Spectrum4_000279
Spectrum5_000707
ST 21
ST 21 (pharmaceutical)
Sulfate, chloroquine
Sulphate, chloroquine
Tanakan
Tanakene
Tresochin
Trochin
UNII-886U3H6UFF
W 7618
WIN 244
WLN: T66 BNJ EMY1&3N2&2 IG
|
|
35 |
|
Fanasil, pyrimethamine drug combination |
|
|
|
|
|
36 |
|
Amodiaquine, artesunate drug combination |
|
|
|
|
|
37 |
|
Amebicides |
|
|
|
|
|
38 |
|
Chloroquine diphosphate |
|
|
|
50-63-5 |
|
39 |
|
Antirheumatic Agents |
|
|
|
|
|
Interventional clinical trials:
(show all 19)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Efficacy of Artesunate Monotherapy and Dihydroartemisinin - Piperaquine in Patients With Uncomplicated Falciparum Malaria in Central Vietnam |
Unknown status |
NCT02604966 |
Phase 4 |
Artesunate (AS) group;DHA - PPQ group |
2 |
Efficacy and Safety of Artesunate + Amodiaquine Combined With a Single Low Dose of Primaquine (0.25 mg/kg) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Zanzibar |
Completed |
NCT03773536 |
Phase 4 |
Artesunate-amodiaquine given with single low dose primaquine |
3 |
Evaluation of the Efficacy of Artemisinin Combination Therapy in Kenya |
Unknown status |
NCT01899820 |
Phase 3 |
Artemether lumefantrine;Dihydroartemisinin piperaquine |
4 |
An Open-label Randomized Controlled Trial to Evaluate the Effectiveness and Safety of a 3 Day Versus 5 Day Course of Artemether-lumefantrine for the Treatment of Uncomplicated Falciparum Malaria in Myanmar |
Completed |
NCT02020330 |
Phase 3 |
Artemether-lumefantrine 3 days;Artemether-lumefantrine 5 days |
5 |
Anti-malarial Drug Resistance in Cameroon: Therapeutic Efficacy and Biological Markers of Resistance |
Completed |
NCT00146718 |
Phase 2, Phase 3 |
Amodiaquine and Sulphadoxine/Pyrimethamine |
6 |
Phase III Clinical Trials of Artemisinin-based Combination Therapy in Cameroon |
Completed |
NCT00297882 |
Phase 3 |
Artemether-Lumefantrine , Amodiaquine-Artesunate |
7 |
A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP |
Completed |
NCT01142765 |
Phase 1, Phase 2 |
|
8 |
A Phase I/IIa Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates AdCh63 MSP1 Alone and With MVA MSP1 |
Completed |
NCT01003314 |
Phase 1, Phase 2 |
|
9 |
Phase 1 Study of the Safety and Immunogenicity of MSP1 42-C1/Alhydrogel With and Without CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria |
Completed |
NCT00320658 |
Phase 1 |
|
10 |
Phase 1 Study of the Safety and Immunogenicity of MSP1(42)-FVO/Alhydrogel and MSP1(42)-3D7/Alhydrogel, Asexual Blood-Stage Vaccines for Plasmodium Falciparum Malaria |
Completed |
NCT00340431 |
Phase 1 |
MSP1(42)-FVO & MSP1(42)-3D7 |
11 |
A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Vivax Malaria Vaccine Candidates ChAd63 PvDBP Alone and With MVA PvDBP |
Completed |
NCT01816113 |
Phase 1 |
|
12 |
Double Blind Randomized Controlled Phase I Trial to Evaluate the Safety and Immunogenicity of WRAIR's MSP1 Candidate Malaria Vaccine (FMP1) Adjuvant in GSK Bio's AS02A vs. Rabies Vaccine in Semi-immune Adults in Bandiagara, Mali. |
Completed |
NCT00308061 |
Phase 1 |
|
13 |
Phase 1 Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel +CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria in Adults in the US and in Bancoumana, Mali |
Completed |
NCT00889616 |
Phase 1 |
BSAM2/Alhydrogel + CPG 7909 |
14 |
Efficacy and Safety of Artesunate+Sulphadoxine-Pyrimethamine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Malaria Control Center Asadabad in Kunar Province of Afghanistan |
Unknown status |
NCT01707199 |
|
Artesunate + Sulphadoxine-pyrimethamine |
15 |
Fetal Immunity to Plasmodium Falciparum Malaria |
Completed |
NCT00314899 |
|
|
16 |
Efficacy of Amodiaquine-Artesunate and Artemether-Lumefantrine for the Treatment of Uncomplicated Childhood Plasmodium Falciparum Malaria in Pweto, Democratic Republic of Congo, 2008 |
Completed |
NCT01567423 |
|
ASAQ Winthrop® Sanofi Aventis;Coartem®, Novartis |
17 |
Efficacy and Safety of Artemether-lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria and Chloroquine for the Treatment of Plasmodium Vivax in the Philippines |
Completed |
NCT04222088 |
|
Arthemeter-lumefantrine;Chloroquine |
18 |
Characterization of Familial Myopathy and Paget Disease of Bone |
Recruiting |
NCT01353430 |
|
|
19 |
Coordination of Rare Diseases at Sanford |
Recruiting |
NCT01793168 |
|
|
Search
NIH Clinical Center
for Inclusion Body Myopathy with Early-Onset Paget Disease with or Without Frontotemporal Dementia 1
|